{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:46:55Z","timestamp":1785847615038,"version":"3.56.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Benderson Family Fund for Triple-Negative Breast Cancer Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10549-026-08039-8","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:15:00Z","timestamp":1785417300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between self-reported breast cancer knowledge and clinical trial participation in patients with triple-negative breast cancer"],"prefix":"10.1007","volume":"218","author":[{"given":"Megan E.","family":"Tesch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Snow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine E.","family":"Stever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonia S.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella G.","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Drummey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katheryn","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Bsat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa E.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Wrabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisar","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Faggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Constantinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L.","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tari A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Mittendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabihah","family":"Tayob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann H.","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5989-6636","authenticated-orcid":false,"given":"Ana C.","family":"Garrido-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"20","key":"8039_CR1","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938\u20131948. https:\/\/doi.org\/10.1056\/NEJMra1001389","journal-title":"N Engl J Med"},{"issue":"22","key":"8039_CR2","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1002\/cncr.27581","volume":"118","author":"NU Lin","year":"2012","unstructured":"Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC (2012) Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118(22):5463\u20135472. https:\/\/doi.org\/10.1002\/cncr.27581","journal-title":"Cancer"},{"issue":"36","key":"8039_CR3","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1200\/JCO.2006.06.5664","volume":"24","author":"BG Haffty","year":"2006","unstructured":"Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36):5652\u20135657. https:\/\/doi.org\/10.1200\/JCO.2006.06.5664","journal-title":"J Clin Oncol"},{"issue":"15 Pt 1","key":"8039_CR4","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429\u20134434. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045","journal-title":"Clin Cancer Res"},{"issue":"3","key":"8039_CR5","doi-asserted-by":"publisher","first-page":"100114","DOI":"10.1016\/j.esmoop.2021.100114","volume":"6","author":"T Grinda","year":"2021","unstructured":"Grinda T, Antoine A, Jacot W, Blaye C, Cottu PH, Dieras V, Dalenc F, Goncalves A, Debled M, Patsouris A, Mouret-Reynier MA, Mailliez A, Clatot F, Levy C, Ferrero JM, Desmoulins I, Uwer L, Petit T, Jouannaud C, Lacroix-Triki M, Deluche E, Robain M, Courtinard C, Bachelot T, Brain E, Perol D, Delaloge S (2021) Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008\u20132017 ESME cohort. ESMO Open 6(3):100114. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100114","journal-title":"ESMO Open"},{"issue":"1","key":"8039_CR6","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1186\/s12885-016-2766-3","volume":"16","author":"A Hennigs","year":"2016","unstructured":"Hennigs A, Riedel F, Gondos A, Sinn P, Schirmacher P, Marme F, Jager D, Kauczor HU, Stieber A, Lindel K, Debus J, Golatta M, Schutz F, Sohn C, Heil J, Schneeweiss A (2016) Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer 16(1):734. https:\/\/doi.org\/10.1186\/s12885-016-2766-3","journal-title":"BMC Cancer"},{"issue":"9","key":"8039_CR7","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O\u2019Shaughnessy J, Investigators K- (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 382(9):810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"issue":"6","key":"8039_CR8","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O\u2019Shaughnessy J, Investigators K- (2022) Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med 386(6):556\u2013567. https:\/\/doi.org\/10.1056\/NEJMoa2112651","journal-title":"N Engl J Med"},{"key":"8039_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409932","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kummel S, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Im SA, Untch M, Fasching PA, Mouret-Reynier MA, Foukakis T, Ferreira M, Cardoso F, Zhou X, Karantza V, Tryfonidis K, Aktan G, O\u2019Shaughnessy J, Investigators K- (2024) Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2409932","journal-title":"N Engl J Med"},{"issue":"10265","key":"8039_CR10","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P, Investigators K- (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396(10265):1817\u20131828. https:\/\/doi.org\/10.1016\/S0140-6736(20)32531-9","journal-title":"Lancet"},{"issue":"3","key":"8039_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P, Investigators K- (2022) Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med 387(3):217\u2013226. https:\/\/doi.org\/10.1056\/NEJMoa2202809","journal-title":"N Engl J Med"},{"key":"8039_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01409","author":"A Bardia","year":"2024","unstructured":"Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Kalinsky K, Cortes J, Shaughnessy JO, Dieras V, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Yoon OK, Pan Y, Hofsess S, Phan SC, Hurvitz SA (2024) Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol:JCO2301409. https:\/\/doi.org\/10.1200\/JCO.23.01409","journal-title":"J Clin Oncol:JCO2301409"},{"issue":"18","key":"8039_CR13","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1200\/JCO.23.01030","volume":"42","author":"JM Unger","year":"2024","unstructured":"Unger JM, Shulman LN, Facktor MA, Nelson H, Fleury ME (2024) National Estimates of the Participation of Patients With Cancer in Clinical Research Studies Based on Commission on Cancer Accreditation Data. J Clin Oncol 42(18):2139\u20132148. https:\/\/doi.org\/10.1200\/JCO.23.01030","journal-title":"J Clin Oncol"},{"issue":"3","key":"8039_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/jnci\/djy221","volume":"111","author":"JM Unger","year":"2019","unstructured":"Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME (2019) Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation. J Natl Cancer Inst 111(3):245\u2013255. https:\/\/doi.org\/10.1093\/jnci\/djy221","journal-title":"J Natl Cancer Inst"},{"key":"8039_CR15","doi-asserted-by":"crossref","unstructured":"Swiger KD, Sendecki JA, Guglielmino JE, Rugo HS, Anders CK, Domchek SM, Ahlum Hanson A, Dinerman H, Creme Henry C (2015) Abstract P2-11-04: education and information preferences for women with triple-negative breast cancer: should personal or medical demographic variables impact program tailoring? Cancer Res. 75(9 Suppl):P2-11-04","DOI":"10.1158\/1538-7445.SABCS14-P2-11-04"},{"issue":"1\u20133","key":"8039_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.pec.2006.03.010","volume":"64","author":"A Fagerlin","year":"2006","unstructured":"Fagerlin A, Lakhani I, Lantz PM, Janz NK, Morrow M, Schwartz K, Deapen D, Salem B, Liu L, Katz SJ (2006) An informed decision? Breast cancer patients and their knowledge about treatment. Patient Educ Couns 64(1\u20133):303\u2013312. https:\/\/doi.org\/10.1016\/j.pec.2006.03.010","journal-title":"Patient Educ Couns"},{"issue":"5","key":"8039_CR17","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/cncr.23262","volume":"112","author":"JY Chen","year":"2008","unstructured":"Chen JY, Diamant AL, Thind A, Maly RC (2008) Determinants of breast cancer knowledge among newly diagnosed, low-income, medically underserved women with breast cancer. Cancer 112(5):1153\u20131161. https:\/\/doi.org\/10.1002\/cncr.23262","journal-title":"Cancer"},{"issue":"8","key":"8039_CR18","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.2105\/ajph.93.8.1271","volume":"93","author":"SN Lukwago","year":"2003","unstructured":"Lukwago SN, Kreuter MW, Holt CL, Steger-May K, Bucholtz DC, Skinner CS (2003) Sociocultural correlates of breast cancer knowledge and screening in urban African American women. Am J Public Health 93(8):1271\u20131274. https:\/\/doi.org\/10.2105\/ajph.93.8.1271","journal-title":"Am J Public Health"},{"issue":"3","key":"8039_CR19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10549-022-06752-8","volume":"196","author":"RA Freedman","year":"2022","unstructured":"Freedman RA, Ko NY, Lederman RI, Gagnon H, Fikre T, Gundersen DA, Revette AC, Odai-Afotey A, Kantor O, Hershman DL, Crew KD, Keating NL (2022) Breast cancer knowledge and understanding treatment rationales among diverse breast cancer survivors. Breast Cancer Res Treat 196(3):623\u2013633. https:\/\/doi.org\/10.1007\/s10549-022-06752-8","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"8039_CR20","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/cncr.28977","volume":"121","author":"RA Freedman","year":"2015","unstructured":"Freedman RA, Kouri EM, West DW, Keating NL (2015) Racial\/ethnic disparities in knowledge about one\u2019s breast cancer characteristics. Cancer 121(5):724\u2013732. https:\/\/doi.org\/10.1002\/cncr.28977","journal-title":"Cancer"},{"issue":"12","key":"8039_CR21","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/pon.1852","volume":"20","author":"VB Sheppard","year":"2011","unstructured":"Sheppard VB, Adams IF, Lamdan R, Taylor KL (2011) The role of patient-provider communication for black women making decisions about breast cancer treatment. Psychooncology 20(12):1309\u20131316. https:\/\/doi.org\/10.1002\/pon.1852","journal-title":"Psychooncology"},{"issue":"6","key":"8039_CR22","doi-asserted-by":"publisher","first-page":"e613","DOI":"10.1200\/JOP.2015.008508","volume":"12","author":"RA Freedman","year":"2016","unstructured":"Freedman RA, Kouri EM, West DW, Lii J, Keating NL (2016) Association of Breast Cancer Knowledge With Receipt of Guideline-Recommended Breast Cancer Treatment. J Oncol Pract 12(6):e613\u2013625. https:\/\/doi.org\/10.1200\/JOP.2015.008508","journal-title":"J Oncol Pract"},{"issue":"31","key":"8039_CR23","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.1200\/JCO.2009.22.9773","volume":"27","author":"NA Bickell","year":"2009","unstructured":"Bickell NA, Weidmann J, Fei K, Lin JJ, Leventhal H (2009) Underuse of breast cancer adjuvant treatment: patient knowledge, beliefs, and medical mistrust. J Clin Oncol 27(31):5160\u20135167. https:\/\/doi.org\/10.1200\/JCO.2009.22.9773","journal-title":"J Clin Oncol"},{"issue":"3","key":"8039_CR24","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/0272989X9701700306","volume":"17","author":"RL Street Jr","year":"1997","unstructured":"Street RL Jr., Voigt B (1997) Patient participation in deciding breast cancer treatment and subsequent quality of life. Med Decis Mak 17(3):298\u2013306. https:\/\/doi.org\/10.1177\/0272989X9701700306","journal-title":"Med Decis Mak"},{"issue":"3","key":"8039_CR25","doi-asserted-by":"publisher","first-page":"e026797","DOI":"10.1136\/bmjopen-2018-026797","volume":"9","author":"ES Hwang","year":"2019","unstructured":"Hwang ES, Hyslop T, Lynch T, Frank E, Pinto D, Basila D, Collyar D, Bennett A, Kaplan C, Rosenberg S, Thompson A, Weiss A, Partridge A (2019) The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open 9(3):e026797. https:\/\/doi.org\/10.1136\/bmjopen-2018-026797","journal-title":"BMJ Open"},{"issue":"5","key":"8039_CR26","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1200\/JCO.2003.02.105","volume":"21","author":"RL Comis","year":"2003","unstructured":"Comis RL, Miller JD, Aldige CR, Krebs L, Stoval E (2003) Public attitudes toward participation in cancer clinical trials. J Clin Oncol 21(5):830\u2013835. https:\/\/doi.org\/10.1200\/JCO.2003.02.105","journal-title":"J Clin Oncol"},{"key":"8039_CR27","doi-asserted-by":"publisher","first-page":"e2500285","DOI":"10.1200\/GO-25-00285","volume":"12","author":"D Horgan","year":"2026","unstructured":"Horgan D, Maravic Z, Mastris K, Mohamad Abu Rasheed H, Reduzzi C, Bounedjar A, Elghazaly H, Mohar A, Pestana R, Lal JA, Malapelle U, Asgary R, Subbiah V (2026) Global Trials, Local Relevance: A Scientific and Regulatory Framework for Regional Enrollment in Cancer Drug Development. JCO Glob Oncol 12:e2500285. https:\/\/doi.org\/10.1200\/GO-25-00285","journal-title":"JCO Glob Oncol"},{"issue":"10466","key":"8039_CR28","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","volume":"404","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Ku M, Hertzberg M, Huang HQ, Fox CP, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Townsend W, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Simko S, Orellana-Noia V, Ta R, Relf J, Dixon M, Kallemeijn M, Mulvihill E, Huang H, Lundberg L, Gregory GP (2024) Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet 404(10466):1940\u20131954. https:\/\/doi.org\/10.1016\/S0140-6736(24)01774-4","journal-title":"Lancet"},{"issue":"3","key":"8039_CR29","doi-asserted-by":"publisher","first-page":"100513","DOI":"10.1016\/j.esmoop.2022.100513","volume":"7","author":"D Presti","year":"2022","unstructured":"Presti D, Havas J, Soldato D, Lapidari P, Martin E, Pistilli B, Jouannaud C, Emile G, Rigal O, Fournier M, Soulie P, Mouret-Reynier MA, Tarpin C, Campone M, Guillermet S, Martin AL, Everhard S, Di Meglio A (2022) Factors associated with enrolment in clinical trials among women with early-stage breast cancer. ESMO Open 7(3):100513. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100513","journal-title":"ESMO Open"},{"issue":"28suppl","key":"8039_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1200\/JCO.2022.40.28_suppl.084","volume":"40","author":"F Lalor","year":"2022","unstructured":"Lalor F, Caston NE, Ingram SA, Wan C, Sussell J, Patel SA (2022) Why aren\u2019t more patients with breast cancer enrolled in clinical trials? J Clin Oncol 40(28suppl):84\u201384. https:\/\/doi.org\/10.1200\/JCO.2022.40.28_suppl.084","journal-title":"J Clin Oncol"},{"issue":"4","key":"8039_CR31","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1200\/JOP.2012.000806","volume":"9","author":"K Miller","year":"2013","unstructured":"Miller K, Abraham JH, Rhodes L, Roberts R (2013) Use of the word cure in oncology. J Oncol Pract 9(4):e136\u2013140. https:\/\/doi.org\/10.1200\/JOP.2012.000806","journal-title":"J Oncol Pract"},{"issue":"2","key":"8039_CR32","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1245\/s10434-024-16390-7","volume":"32","author":"C Connors","year":"2025","unstructured":"Connors C, Valente SA, ElSherif A, Escobar P, Chichura A, Kopicky L, Roesch E, Ritner J, McIntire P, Wu Y, Tu C, Lang JE (2025) Real-World Outcomes with the KEYNOTE-522 Regimen in Early-Stage Triple-Negative Breast Cancer. Ann Surg Oncol 32(2):912\u2013921. https:\/\/doi.org\/10.1245\/s10434-024-16390-7","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"8039_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1200\/JOP.0922001","volume":"5","author":"RL Comis","year":"2009","unstructured":"Comis RL, Miller JD, Colaizzi DD, Kimmel LG (2009) Physician-related factors involved in patient decisions to enroll onto cancer clinical trials. J Oncol Pract 5(2):50\u201356. https:\/\/doi.org\/10.1200\/JOP.0922001","journal-title":"J Oncol Pract"},{"issue":"1","key":"8039_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cdp.2005.12.001","volume":"30","author":"CR Baquet","year":"2006","unstructured":"Baquet CR, Commiskey P, Daniel Mullins C, Mishra SI (2006) Recruitment and participation in clinical trials: socio-demographic, rural\/urban, and health care access predictors. Cancer Detect Prev 30(1):24\u201333. https:\/\/doi.org\/10.1016\/j.cdp.2005.12.001","journal-title":"Cancer Detect Prev"},{"issue":"2","key":"8039_CR35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3747\/co.25.3857","volume":"25","author":"A Mahmud","year":"2018","unstructured":"Mahmud A, Zalay O, Springer A, Arts K, Eisenhauer E (2018) Barriers to participation in clinical trials: a physician survey. Curr Oncol 25(2):119\u2013125. https:\/\/doi.org\/10.3747\/co.25.3857","journal-title":"Curr Oncol"},{"issue":"9","key":"8039_CR36","doi-asserted-by":"publisher","first-page":"e849","DOI":"10.1200\/JOP.19.00662","volume":"16","author":"AR Wong","year":"2020","unstructured":"Wong AR, Sun V, George K, Liu J, Padam S, Chen BA, George T, Amini A, Li D, Sedrak MS (2020) Barriers to Participation in Therapeutic Clinical Trials as Perceived by Community Oncologists. JCO Oncol Pract 16(9):e849\u2013e858. https:\/\/doi.org\/10.1200\/JOP.19.00662","journal-title":"JCO Oncol Pract"},{"issue":"12","key":"8039_CR37","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1200\/JCO.2003.09.124","volume":"21","author":"MM Kemeny","year":"2003","unstructured":"Kemeny MM, Peterson BL, Kornblith AB, Muss HB, Wheeler J, Levine E, Bartlett N, Fleming G, Cohen HJ (2003) Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 21(12):2268\u20132275. https:\/\/doi.org\/10.1200\/JCO.2003.09.124","journal-title":"J Clin Oncol"},{"issue":"11","key":"8039_CR38","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1200\/JCO.2004.03.005","volume":"22","author":"MS Simon","year":"2004","unstructured":"Simon MS, Du W, Flaherty L, Philip PA, Lorusso P, Miree C, Smith D, Brown DR (2004) Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol 22(11):2046\u20132052. https:\/\/doi.org\/10.1200\/JCO.2004.03.005","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"8039_CR39","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1200\/JCO.2022.40.16_suppl.1014","volume":"40","author":"S Walker","year":"2022","unstructured":"Walker S, Carlson M, White CB, Howell J, Felder TM (2022) Increasing Black patient participation in metastatic breast cancer clinical trials: The BECOME (Black Experience of Clinical Trials and Opportunities for Meaningful Engagement) project. J Clin Oncol 40(16suppl):1014\u20131014. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.1014","journal-title":"J Clin Oncol"},{"issue":"2","key":"8039_CR40","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1245\/s10434-021-10868-4","volume":"29","author":"MF Eskander","year":"2022","unstructured":"Eskander MF, Gil L, Beal EW, Li Y, Hamad A, Oppong B, Obeng-Gyasi S, Tsung A (2022) Access Denied: Inequities in Clinical Trial Enrollment for Pancreatic Cancer. Ann Surg Oncol 29(2):1271\u20131277. https:\/\/doi.org\/10.1245\/s10434-021-10868-4","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"8039_CR41","doi-asserted-by":"publisher","first-page":"pkz103","DOI":"10.1093\/jncics\/pkz103","volume":"4","author":"OM Fayanju","year":"2020","unstructured":"Fayanju OM, Ren Y, Thomas SM, Greenup RA, Hyslop T, Hwang ES, Stewart JH (2020) A Case-Control Study Examining Disparities in Clinical Trial Participation Among Breast Surgical Oncology Patients. JNCI Cancer Spectr 4(2):pkz103. https:\/\/doi.org\/10.1093\/jncics\/pkz103","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"8039_CR42","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1001\/jamaoncol.2015.3924","volume":"2","author":"JM Unger","year":"2016","unstructured":"Unger JM, Gralow JR, Albain KS, Ramsey SD, Hershman DL (2016) Patient Income Level and Cancer Clinical Trial Participation: A Prospective Survey Study. JAMA Oncol 2(1):137\u2013139. https:\/\/doi.org\/10.1001\/jamaoncol.2015.3924","journal-title":"JAMA Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08039-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08039-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08039-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:54:25Z","timestamp":1785844465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08039-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8039"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08039-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"23 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice Standards and the Declaration of Helsinki. Institutional review board (IRB) approval was obtained. Women and men of all races and ethnic groups were eligible for the trial. All participants provided written informed consent prior to the performance of any protocol specific procedures or assessments.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent prior to the performance of any protocol specific procedures or assessments.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tari A. King reports compensated advisory board service and consulting for Exact Sciences and Veracyte; and compensated advisory board service for GE HealthCare (FES-PET Steering Committee) and Ataraxis AI. Elizabeth A. Mittendorf reports compensated service on scientific advisory boards for AstraZeneca, BioNTech, and Merck; uncompensated service on steering committees for Bristol Myers Squibb and Roche\/Genentech; speakers honoraria and travel support from Merck Sharp & Dohme; and institutional research support from Roche\/Genentech (via SU2C grant) and Gilead. EAM also reports research funding from Susan Komen for the Cure for which she serves as a Scientific Advisor, and uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. Nancy U. Lin reports institutional research support for Genentech, Pfizer, Merck, Seattle Genetics, Zion Pharmaceuticals (as part of Roche\/GNE), Olema Pharmaceuticals, AstraZeneca, Iksuda, and Stemline\/Menarini; consulting honoraria for Pfizer\/Seagen, Daiichi Sankyo, AstraZeneca, Olema Pharmaceuticals, Stemline\/Menarini, Artera Inc., Eisai, Shorla Oncology, Denali Therapeutics, and Genentech; royalties \u2013 UpToDate (book); and travel support from Olema, AstraZeneca, and Daiichi Sankyo. Ann H. Partridge reports receiving royalties from Wolters Kluwer. Sara M. Tolaney reports consulting or advisory roles for Novartis, Pfizer\/Seagen, Merck, Eli Lilly, AstraZeneca, Genentech\/Roche, Eisai, Bristol Myers Squibb\/Systimmune, Daiichi Sankyo, Gilead, Blueprint Medicines, Reveal Genomics, Artios Pharma, Menarini\/Stemline, Bayer, Jazz Pharmaceuticals, Cullinan Oncology, Circle Pharma, Arvinas, BioNTech, Launch Therapeutics, Zuellig Pharma, Johnson&Johnson\/Ambrx, Bicycle Therapeutics, BeiGene Therapeutics, Mersana, Summit Therapeutics, Avenzo Therapeutics, Aktis Oncology, Celcuity, Boehringer Ingelheim, Samsung Bioepis, Olema Pharmaceuticals, Tempus, Boundless Bio, Denali Therapeutics, Relay Therapeutics, Corcept, Ottima Pharma, and Ellipses Pharma; Scientific Advisory Board service for Valanx BioTech; research funding from Genentech\/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, AstraZeneca, NanoString Technologies, Gilead, Seagen, OncoPep, Daiichi Sankyo, Menarini\/Stemline, Jazz Pharmaceuticals, and Olema Pharmaceuticals; and travel support from Lilly, Gilead, Jazz Pharmaceuticals, Pfizer, Roche, and AstraZeneca. Ana C. Garrido-Castro reports research support (to Institution) from AstraZeneca, Bicycle Therapeutics, Biovica, BioNTech, Bristol-Myers Squibb, Case45, Daiichi Sankyo, Foundation Medicine, Gilead Sciences, Merck & Co., Novartis, Precede Biosciences, Zenith Epigenetics, and 4D Path; Scientific Advisory Board service and consulting for AstraZeneca, Daiichi Sankyo, Gilead Sciences, Novartis, Pfizer, and TD Cowen; Steering Committee service for AstraZeneca, Daiichi Sankyo, and Merck & Co.; serving as a speaker for\/honoraria from AstraZeneca, Bicycle Therapeutics, Daiichi Sankyo, Gilead Sciences, and Roche\/Genentech; and travel or other support from AstraZeneca, Daiichi Sankyo, Gilead Sciences, Merck & Co., Novartis, Pfizer, and Roche\/Genentech. The remaining authors declare no conflicts of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26"}}